Download full-text PDF

Source

Publication Analysis

Top Keywords

[letter test
4
test propranolol
4
propranolol clinical
4
clinical study
4
study asthmatic
4
asthmatic diathesis]
4
[letter
1
propranolol
1
clinical
1
study
1

Similar Publications

Greater neighborhood disadvantage is associated with poorer global cognition. However, less is known about the variation in the magnitude of neighborhood effects across individual cognitive domains and whether the strength of these associations differs by individual-level factors. The current study investigated these questions in a community sample of older adults ( = 166, mean age = 72.

View Article and Find Full Text PDF

Zellweger spectrum disorder presenting with opsoclonus-myoclonus-ataxia syndrome: a case report on immunotherapy.

Acta Neurol Belg

January 2025

Department of Pediatrics, Neurology Unit, University of Health Sciences, Ankara Etlik City Hospital, Ankara, Turkey.

Introduction: Zellweger spectrum disorder (ZSD) refers to a group of autosomal recessive genetic disorders that affect multiple organ systems and are predominantly caused by pathogenic variants in PEX genes. ZSD present a wide clinical spectrum, ranging from the most severe form, Zellweger syndrome, to the mildest form, Heimler syndrome.

Case Report: A 14-month-old male patient was brought to our clinic with recent-onset ocular tremors and unsteady gait.

View Article and Find Full Text PDF

Cultural Effects on the Performance of Older Haitian Immigrants on Timed Cognitive Tests.

Med Res Arch

November 2024

Department of Electrical Engineering and Computer Science, Florida Atlantic University, 777 Glades Road, EE 428 & 526, Boca Raton, FL, 33431.

Background: Ignoring the cultural factors that can affect performance on cognitive tests may result in use of tests that have not been validated for that group. One example is testing of Haitian Creole speaking adults who are increasingly affected by Alzheimer's disease and related dementias, for whom few tests have been validated.

Aims: Our purpose is to describe differences in timed test performance between Haitian Creole and English-speaking participants and explore factors that may account for any differences in results found.

View Article and Find Full Text PDF

Bosutinib for the Treatment of CML-Using it Safely: a Podcast.

Target Oncol

January 2025

Division of Hematology and SCT, Georgia Cancer Centre, Augusta, GA, USA.

Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!